Life Sciences
QIAGEN expands AI in bioinformatics and drug discovery
QIAGEN expanded AI across bioinformatics and drug discovery, including a natural-language research assistant and additional clinical-interpretation capabilities.
QIAGEN introduced AI capabilities intended to help researchers analyze biological and genomic information and automate selected parts of drug-discovery workflows. Its IPA Investigator allows users to pose biological questions in natural language, identify relevant relationships, recommend analyses, and conduct those analyses within the platform. QIAGEN is also expanding AI-enabled translation in Clinical Insight Interpret and combining machine learning with expert-reviewed information in Franklin. These developments demonstrate a move toward natural-language interfaces and workflow automation in bioinformatics. The available report does not establish clinical performance or regulatory clearance for the tools.
Original source: Digital Health News